Introduction {#sec1}
============

Each year nearly 200 000 new cases of kidney tumors are diagnosed worldwide \[[@cit0001]\]. Due to the common use of abdominal ultrasonography (US), computed tomography (CT) and/or magnetic resonance imaging (MRI), most of the small renal masses (SRM, i.e., less than 4 cm) are discovered incidentally in asymptomatic patients and at an early clinical stage. Stage T1 renal tumors (i.e., organ-confined and not exceeding 7 cm) account for \> 60% of cases. A lot of controversies remain regarding the management of SRM. At the end of the 20^th^ century, partial nephrectomy (PN) evolved from a rare procedure to the current standard of care, lessening the risk of chronic kidney disease and (possible) death by other causes in kidney cancer survivors. As shown in the literature, when the size and stage of kidney tumor development are low, there appears to be a very limited risk of metastasis and cancer-specific mortality \[[@cit0002]\]. As a consequence, over the last decade, alternative and much less invasive methods (i.e., ablative techniques) have been developed and evaluated. Due to the lack of adequate oncologic follow-up and several drawbacks, such as accuracy of pre- and postablation biopsy, the need for frequent imaging, and the high rate of benign pathology in SRM, ablative techniques are still being reserved for patients unfit for surgery. Importantly, in the group of elderly patients, especially those with comorbidities and/or who are at surgical risk, active surveillance (AS) becomes a preferable approach.

Finding an appropriate option of SRM management in poor surgical candidates is challenging. With the intention of making the right decision, one main problem needs to be debated -- should it be an invasive or non-invasive way of management? Which one will bring better life expectancy, fewer complications and a better quality of life? There are lots of factors that need to be faced -- most of all, the tumor size, patient's age and co-morbidities. Active surveillance is more advocated in elderly patients than radiofrequency ablation or cryoablation. However, the long-term effect of the ablations procedures is more stable and easier to predict compared to AS. This article will focus on describing the practical aspects of AS and the ablation techniques used in the management of SRM in surgically unfit patients.

Material and methods {#sec2}
====================

We performed an English language literature search in PubMed/Medline in July 2018 using the following keywords: focal therapy, small renal masses, renal ablation, cryoablation, radiofrequency ablation, HIFU, microwave ablation, renal cell carcinoma (RCC). We looked through articles written in English between 2002 and 2018. Review articles, case reports, comments and editorials as well as congress abstracts were excluded. Studies that combined RCC outcomes with those of primary tumors other than RCC were excluded as well. Additional relevant articles were selected from manuscript bibliographies. Given the retrospective, mostly non-comparative design of the identified studies, the evidence synthesis was performed in a descriptive and narrative manner. For the purpose of the current review 61 articles published between 2002 and 2018 were selected.

Results {#sec3}
=======

Management of small renal masses {#sec3.1}
--------------------------------

### Active surveillance {#s3a1}

Active surveillance is one of the methods used more and more frequently in the management of SRM in elderly and/or high surgical risk patients. It appears to be a safer and more sensible approach than previously thought \[[@cit0003]\]. It is based on making a series of follow-up CT, MRI scans or other radiological imaging revealing any possible tumor progression \[[@cit0004]\]. The DISSRM protocol advises CT or MRI with contrast at the beginning, to be followed by CT or MRI every 4 to 6 months for 2 years and then every 6 to 12 months thereafter \[[@cit0005]\]. A high percentage of SRM are benign and can be safely managed with monitoring. Furthermore, SRM feature slow growth rates (0.1--0.3 cm per year). This allows AS to be made available for this kind of lesions \[[@cit0006]\]. What is more, by selecting this option, several factors must be considered: tumor characteristics and location, risk of hemodialysis after intervention in the course of serious renal insufficiency, patient's age and negative attitude to this way of management, and mortality. Therefore, some patients with SRM may be safely observed but should be under close monitoring for tumor growth \[[@cit0007]\]. The role of a percutaneous needle biopsy appears also promising in the management of SRM. If the biopsy confirms the presence of a non-malignant lesion, surgical intervention or even a follow-up could be potentially avoided \[[@cit0008]\]. A common outcome is that the lesion is not a tumor at all. The surveillance approach is particularly designed for elders with multiple co-morbidities to avoid risk associated with surgical operations, such as partial nephrectomy \[[@cit0002]\]. Active surveillance is an option for these people and for those who choose not to have surgery because of fear or any other personal reasons. The age of 75 or over is accepted especially to consider AS owing to satisfactory life expectancy \[[@cit0009]\]. Among 445 elderly patients under the AS protocol, overall survival (OS) was 96% at 2 years, and 75% at 5 years, cancer-specific survival (CSS) 100% at 5 years \[[@cit0005]\]. Active surveillance is not recommended in young patients due to the low but real danger of expansion of a metastatic disease \[[@cit0002]\]. This group is rather treated with invasive procedures. Financial expenses are another advantageous aspect of AS. Radiological follow-up imaging generates significantly lower costs than even minimally invasive procedures. Nevertheless, as advised by Azawi *et al.*, caution should be taken when offering AS. An analysis of the AS approach on 106 patients with SRM showed that metastases were discovered in 2.9% of examined patients even after surgical operations of masses smaller than 4 cm. Therefore, AS must be limited to patients with a short life expectancy. Wider applicability of AS may be possible in the future. By choosing AS, all precautions should be taken, because even SRM could be aggressive \[[@cit0010]\].

### Ablative therapies {#s3a2}

Nephron-sparing surgery (NSS) is the gold standard in SRM management. However, in recent years we can observe a clear tendency towards focal destruction of cancer tissue, i.e. ablations or AS. That trend expresses the development and necessity of conservative treatment especially in patients at surgical risk. Several ablative techniques are commonly used nowadays when it comes to treatment of SRM. The most widely investigated and applied are cryoablation (CA) and radiofrequency ablation (RFA). Methods such as microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) are being developed and evaluated. When compared to surgical therapy, minimally invasive ablative techniques present several advantages including reduction of pain and blood loss, which lead to a shorter hospital stay. Dynamic improvement of ablative techniques, development of new technologies and increasing experience of the operators give new treatment patterns to patients who are poor surgical candidates, especially with anatomically uncomplicated SRM. Furthermore, short hospitalization and cost-effectiveness of ablative therapies are promising in comparison to NSS, especially for the percutaneous approach \[[@cit0011], [@cit0012]\]. As far as oncological outcome is concerned, some studies show a benefit of NSS over ablative techniques and others give no evidence of significant difference between these two approaches considering metastatic disease, progression or local recurrence \[[@cit0013], [@cit0014]\]. Each ablative therapy has its own advantages, which are described in detail below and summarized in [Table I](#t0001){ref-type="table"}.

###### 

Comparison of non-invasive treatment options for small renal masses

  Management of small renal masses in patients at surgical risk   Advantages                                                                                Disadvantages
  --------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Active surveillance                                             Low costOutpatient care possibleApproved for elderly and frail individuals                No long-term dataRequires close follow-upMight put some patients at risk as no local treatment given
  Cryoablation                                                    Confirmed efficiencyWell developed technicallyPresence of "ice ball" during procedure     No long-term follow-up
  Radiofrequency ablation                                         Confirmed efficiencyWell developed technically                                            No significant real-time changes during procedure"Heat sink" effectNo long-term follow-up
  Microwave ablation                                              Shorter time of procedureMinor procedural painAbility to cover multiple SRM at once       There is not enough research confirming efficiency
  High-intensity focused ultrasound                               Extracorporeal approach which reduces complications                                       Improvement is needed due to high number of incomplete ablations
  Irreversible electroporation                                    No "heat sink" effect -- suitable for masses located near vessels and collecting system   There is not enough research confirming efficiency

Cryoablation {#sec3.2}
------------

The procedure is based on use of the cryoprobes depressurization argon or helium gas, giving typically two freeze--thaw cycles achieved by the Joule-Thomson effect \[[@cit0015]\]. A range of low temperatures from --40°C to --60°C (depending on tissue type) is required to achieve formation of ice crystals (known as iceballs) within cells, organelle damage, disruption of cell membrane, dehydration and consequently apoptosis, as well as the cell death cascade \[[@cit0016], [@cit0017]\]. Subsequent thawing results in cell edema and bursting due to the influx of extracellular fluid. Moreover, vascular thrombosis inducing local ischemia is the cause of impaired tissue repair \[[@cit0015], [@cit0018]\]. Histologically, cryoablation results in occurrence of cholesterol crystals, dystrophic calcification and histiocyte influx (indicating coagulative necrosis) as well as hemorrhage within the margin of the ablation zone. Eventually fibrotic changes and scarring substitute the cryoablated lesion \[[@cit0019], [@cit0020]\]. Apart from the area of the mass the whole procedure takes into account a 5 to 10 mm margin constituting the ablation zone and is monitored in real time by thermocoupling or ultrasonography. Optimal results can be achieved by using multiple cryoprobes, which should be placed 1.5 cm apart and no more than 1 cm from the edge of the mass. The shape and size of the ablation zone can be customized by activation or deactivation of some cryoprobes during the procedure, giving the interventional radiologist the ability to actively monitor the ablation zone via US, CT or MRI due to iceball formation \[[@cit0021]\]. Moreover, the extent of the ablation zone is dependent on cryoprobe manufacturer or cryoprobe size \[[@cit0022]\]. In the case of cryoablation, two approaches are performed: percutaneous (PCA) and open/laparoscopic surgical (SCA) \[[@cit0023], [@cit0024]\]. Selection of the method is primarily determined by location of the mass. Although the choice of the approach still seems to depend on the performing surgeon or institutional traditions, studies indicate that percutaneous cryoablation is associated with shorter hospital stay and lower hospital costs compared to the surgical approach. Technical success rate, major complication rate and mean follow-up time show no significant difference between percutaneous and laparoscopic cryoablation \[[@cit0025], [@cit0026]\].

Radiofrequency ablation {#sec3.3}
-----------------------

Radiofrequency ablation (RFA) uses alternating current of around 500 kHz frequency, delivered through a probe to gain radiofrequency waves. It causes coagulative necrosis of target cells and surrounding margins with temperature 50--100°C. There are a few systems controlling overheating of a needle, such as internal liquid cooling, pulsed delivery of energy, measuring impedance of a tissue or direct temperature of electrode in order to prevent vaporization and carbonization of the treated area \[[@cit0027]\]. Contrary to cryoablation, the operator cannot see any significant changes in mass appearance in real time during the procedure since heat energy distribution cannot be assessed on CT or US images. The percutaneous approach is used for treatment of posterior and lateral masses due to separation from intraperitoneal organs. For anteriorly located tumors laparoscopic RFA is generally required \[[@cit0028]\]. Radiofrequency ablation enables one to shorten hospitalization, and decreases complications and procedural costs \[[@cit0029]\]. Findings indicate that noncentral location and small size of masses raise the effectiveness of this method. Otherwise, for central tumors the "heat sink" effect can be observed due to spreading of energy brought in by the urinary tract system and local vessels \[[@cit0030]\].

Microwave ablation {#sec3.4}
------------------

The general principle, as in RFA, is to obtain a rise of a temperature in a specific location. However, it varies in the frequency of electrical current (0.9--2.5 GHz), which belongs to the microwave spectrum \[[@cit0031]\]. Circulation of this current in a probe induces movements of water molecules in surrounding tissues so heat is produced and coagulative necrosis is observed \[[@cit0027]\]. The aim is to reach at least 60°C on target, measured by thermocouples \[[@cit0015]\]. In comparison to other ablation techniques MWA provides: higher temperatures if needed, covering larger and multiple volumes of SRM at once, shorter time of ablation and minor pain for a patient \[[@cit0032]\]. One of the studies revealed that 3-year survival of the patients after MWA (91.3%) was similar to those after partial nephrectomy (96%) \[[@cit0033]\].

High-intensity focused ultrasound {#sec3.5}
---------------------------------

To achieve necrosis focused ultrasound waves are used. A heat of more than 65°C is obtained due to converting absorbed energy. Besides the noninvasive mechanism and sparing of surrounding tissues there are limitations, such as target depth, variability and movements. The exposure time and its intensity are crucial because of acoustic cavitation as a substitution for thermal necrosis. That leads to mechanical lysis and unpredictable changes caused by microbubbles' movement under high pressure \[[@cit0034]\]. Findings reveal that extracorporeal HIFU can result in incomplete ablation while the laparoscopic approach appears to be more effective; however, further studies are needed \[[@cit0035]\].

Irreversible electroporation {#sec3.6}
----------------------------

Irreversible electroporation is a non-thermal method using microsecond electrical pulses. The aim is to form nano-scale pores in membranes of ablated cells. This permeabilization leads to their death with minimal inflammation in surrounding tissue \[[@cit0036]\]. Moreover, connective tissue remains unchanged after the treatment and blood flow does not have an influence on energy given to ablated tissue. Therefore the 'heat sink' effect is not observed, which is promising for masses located close to blood vessels or the renal collecting system \[[@cit0037]--[@cit0039]\]. The latest findings showed that urothelium, 28 days after IRE, after temporary degeneration, starts to regenerate, whereas tumor cells and parenchyma are destroyed permanently \[[@cit0040]\].

Ablation approach {#sec3.7}
-----------------

From all of the ablation methods described above only HIFU can be performed extracorporeally. Despite being the least invasive, effectiveness does not appear to reach a satisfactory level. Clinical efficacy differs in many studies, the rate of successful ablations usually being around 60% \[[@cit0034]\]. There is no cumulative dose effect so a repeat procedure is possible. Other techniques are performed by a percutaneous, laparoscopic or open approach. The latter will not be described in this review because open surgery is not desirable for mentioned patients with SRM, whereas laparoscopic technique is particularly useful for anterior tumors where there exists higher probability of damaging adjacent organs. Compared to laparoscopic NSS a lower complication rate is observed, but there is a higher probability of local recurrence \[[@cit0003], [@cit0041]\]. Considering patient comorbidities and the general state of health which indicate that reducing the risk of procedural complications is essential, laparoscopic ablation is desirable for that group when the mentioned approach is needed.

Percutaneous ablations are suitable for posteriorly and laterally located masses, which can be accessed easily. Less invasive treatment and gradually better real-time imaging resulted in a predominantly performed percutaneous approach. For masses adjacent to the bowel hydrodissection provides a safe distance from a probe and overheating of surrounding structures by forming thermal insulation. It is especially indicated for patients with impaired renal function or a single kidney because of the slightly reduced nephrons number. Another advantage is quicker recovery with minor complications, which favorably affects the patients' comorbidities \[[@cit0042]\]. Short-term oncological outcomes are similar to partial nephrectomy, so if possible, percutaneous ablation should be performed \[[@cit0041], [@cit0043]\]. Summing up, if there is an indication to perform ablation in poor surgical candidates, location of a tumor is the most crucial aspect of the decision ([Figure 1](#f0001){ref-type="fig"}).

![Choosing an ablation approach depending on the location of a tumour](AMS-16-5-37017-g001){#f0001}

Renal tumor biopsy {#sec3.8}
------------------

The selection of optimal treatment also depends on tumor characteristics. Particularly in poor surgical candidates, knowledge of whether the mass is benign or malignant can lead to different management options. Also low-nuclear grading malignant tumor could be observed instead of not recommended surgical treatment for those patients. Therefore, the identification of benign lesion can be useful for assignment to active surveillance instead of intervention. However, most of the renal biopsies are performed at the time of ablation instead of the pre-treatment procedure. That excludes the ability to avoid unnecessary intervention, which is especially important for the mentioned patients. Associated risk of biopsy is below 1% of complications and results in minimal consequences; nonetheless, its usefulness is still discussed \[[@cit0044]\]. Patients with short life expectancy are not required to undergo biopsy because the further decision of AS will be independent of its result \[[@cit0045]\].

Discussion {#sec4}
==========

Choosing the best treatment option for SRM is discussed due to the existence of a wide range of methods. Particularly in poor surgical candidates the choice is hindered due to the general state of their health. The decision about the intervention depends on many factors: age and life expectancy, comorbidities, impairment of renal function or presence of a solitary kidney, size, location and characteristics of a tumor or patient's wish. The current standard for management of SRM is partial nephrectomy; however, a higher complication rate and inevitability of general anaesthesia incline to a less invasive procedure for mentioned patients.

Patel *et al.* stated that in the short/intermediate term AS provides an alternative therapy to surgery. In comparison to partial and radical nephrectomy, overall and cancer-specific survival were not significantly different. Patients who underwent AS were older and the mean tumor size was smaller than those who were treated by surgery. 19.7% of a group managed with AS later received definitive treatment because of an increase in size of the mass, patient choice or alteration in radiological diagnosis \[[@cit0002]\]. That confirms the necessity of monitoring actual tumor progression and the utility of AS for patients with short life expectancy. Uzosike *et al.* observed, in a group of patients who were under AS, that no one died from kidney cancer or developed metastasis during the follow-up period. Growth rates of renal masses decreased with time of observation, which indicates a need for more frequent imaging especially at the beginning of AS \[[@cit0046]\]. Abouassaly *et al.* conducted an analysis of the treatment strategy for incidentally detected SRM on a wide range of patients. The age of 75 was the point when AS and/or ablative therapy appear to be a preferable and safe approach. Younger patients should be managed with initial active intervention, i.e. NSS. As the authors highlighted, results can vary from retrospective data by taking into consideration under-representation of patients in a poor state of health \[[@cit0009]\]. Jewett *et al.* investigated the mean tumor growth rate of 209 SRM in elderly patients. The average follow-up was 28 months and the increase in tumor diameter was 0.13 cm/year. Moreover, local progression was observed in 12% and biopsy-proven presence of renal cell carcinoma did not substantially change the growth rate of masses. That indicates the utility of AS in infirm patients to avoid invasive treatment \[[@cit0047]\].

Psutka *et al*. presented long-term oncologic outcomes for RFA (median follow-up: 6.43 years). This study revealed that 92.3% of patients with T1a tumors were disease free and local recurrences occurred in only 4.2%. If a T1b tumor was present outcomes respectively reached 76.2% and 14.3%. That indicates the necessity of long-term observation in RFA patients, especially in higher stage tumors \[[@cit0048]\]. Zachos *et al*. reported that 90.6% of RFA under US guidance was primarily effective with no residual cT1a masses \[[@cit0049]\]. Wah *et al*. examined outcomes of RFA on 200 tumors \[[@cit0050]\]. Five percent of patients had major complications such as ureteric injury, abscess, acute tubular necrosis or calyceal-cutaneous fistula. Two percent developed significant renal function deterioration. Five-year OS was 75.8%, CCS 97.9%, local recurrence-free (LRFS) 93.5% and metastasis-free survival (MFS) 87.7% \[[@cit0050]\]. Kunkle and Uzzo conducted a meta-analysis of SRM treatment by RFA and CA on a group of 1375 kidney lesions. Repeated ablation had to be performed in 8.5% of RFA and 1.3% of CA. Local tumor progression reached respectively 12.9% and 5.2%, which suggest superiority of the second method. In the mentioned analysis 65% of CA was laparoscopically performed and 94% of RFA percutaneously, so outcomes could have varied from actual \[[@cit0051]\]. Particularly for elderly patients the crucial issue of fewer complications outweighs the laparoscopic ablation approach. However, in recent years there has been tendency to perform percutaneously also CA \[[@cit0041]\]. Atwell *et al*. compared CA and RFA in this approach. Outcomes were promising and similar for each method with inconsiderable superiority of RFA in local recurrence-free survival rates \[[@cit0052]\]. Importantly, there are many recent studies supporting the increasing role of both RFA and CA in the management of small renal masses \[[@cit0053]--[@cit0055]\].

Wah *et al.* reported that the efficacy of RFA can be predicted using dynamic contrast enhanced (DCE)-MRI. The perfusion of RCCs was examined in 21 patients who underwent RFA. The authors concluded that 1 month following ablation the perfusion significantly decreased in comparison to the pre-treatment measurement. Analyzing RCC blood flow enables early effects of RFA to be detected \[[@cit0056]\]. There is also a growing trend in using ultrasound contrast media not only to monitor the ablation procedures in real time but also in the follow-up imaging to screen for residual tumor \[[@cit0057]\].

Furthermore, ablative procedures can lead to post-ablation syndrome. Zhong *et al.* examined percutaneous CA and its influence on fever and flu-like symptoms. Only 6 of 64 patients (9%) developed post-ablation syndrome and 33 (52%) patients developed flu-like symptoms only \[[@cit0058]\].

Wu *et al.* treating advanced renal cell carcinoma with HIFU obtained reduction of pain and hematuria in all 10 patients with no sign of total ablation \[[@cit0059]\]. Then Marberger *et al.* reported that extracorporeal HIFU resulted in incomplete ablation of target tissue in all 18 cases \[[@cit0060]\]. Klingler *et al.* reported that in the laparoscopic approach all 31 patients who underwent this procedure using the new transducers demonstrated complete ablation \[[@cit0061]\]. Not only are multicenter studies on a larger group of patients treated with HIFU needed but also technical improvement of the method appears necessary. Similarly, MWA and IRE require further investigations. Current data do not allow them to be compared with other ablative methods and to definitely choose them. The clinical outcomes of SRM treatment by AS, RFA and CA are presented in [Table II](#t0002){ref-type="table"}.

###### 

Clinical outcomes of SRM management

  Authors                                          Management   Number of tumors            Tumor diameter \[cm\]      Median follow-up \[months\]    Results
  ------------------------------------------------ ------------ --------------------------- -------------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------
  Patel *et al.* \[[@cit0002]\]                    AS           71                          2.2                        34                             Mean growth rate 0.21 cm/yearOS 83%, CSS 98.6% -- no significant difference between PN and RN
  Pierorazio *et al.* \[[@cit0005]\]               AS           223                         1.9                        25                             OS at 2 years 96%, at 5 years 75%,CSS at 5 years 100%
  Jewett *et al*. \[[@cit0047]\]                   AS           178                         2.1                        28                             Mean growth rate 0.13 cm/yearLocal progression in 12% and 1.1% with metastases
  Psutka *et al*. \[[@cit0048]\]                   RFA          185                         3.0                        77                             Local recurrence 6.5%CSS at 5 years 99.4%Residual tumor in 13%T1b patients presented significantly worse clinical outcome than T1a
  Zachos *et al.* \[[@cit0049]\]                   RFA          32                          2.4                        22                             Residual tumor in 3%Local recurrence in 9.4%
  Wah *et al.* \[[@cit0050]\]                      RFA          200                         2.9                        46.1                           5-year OS, CSS, LRFS and MFS rates of 75.8%, 97.9%, 93.5% and 87.7% respectively
  Kunkle and Uzzo (meta-analysis) \[[@cit0051]\]   RFA and CA   1375 (775 RFA and 600 CA)   2.6                        18.7                           Local recurrence in 12.9% RFA and 5.2% CAResidual tumor in 8.5% and 1.3% respectivelyProgression to metastases in 1.0% and 2.5% respectively
  Atwell *et al.* \[[@cit0052]\]                   RFA and CA   445 (256 RFA and 189 CA)    1.9 in RFA and 2.3 in CA   33.6 for RFA and 10.8 for CA   Local recurrence in 3.2% RFA and in 2.8% CAMajor complications after 4.3% and 4.5% respectively

AS -- active surveillance, RFA -- radiofrequency ablation, CA -- cryoablation, OS -- overall survival, CSS -- cancer-specific survival, LRFS -- local recurrence-free survival, MFS -- metastasis-free survival, PN -- partial nephrectomy, RN -- radical nephrectomy.

In conclusion, choosing the optimal treatment option in poor surgical candidates diagnosed with SRM requires consideration of the general condition of the patients, their life expectancy and comorbidities. Particularly when a patient does not agree to any intervention, may not survive it or the renal mass is around 2 cm, AS should be offered. Follow-up observation provides information about the tumor growth rate so treatment can be altered depending on the situation. Only if the tumor diameter reaches a size of around 4 cm and there are no contraindications is percutaneous ablation recommended. Radiofrequency ablation or CA is advisable due to the confirmed intermediate-term oncological efficacy. Microwave ablation and IRE need further investigations in larger group of patients. However, MWA may replace in the future first-line techniques due to the shorter time of ablation and less procedural pain. Irreversible electroporation might become used for tumors located close to vessels or renal collecting system. The extracorporeal approach of HIFU is promising but technical improvement of the method is vital to reduce the number of incomplete ablations.
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